ECO AI PA Parth Agrawal Tokenomics Daily — Nobody Picks ‘The Best Model’ Anymore. Not Even OpenAI. Two stories today, three days apart, say the same thing from opposite sides of the table. Vercel’s CEO says his customers stopped picking…
BIO TCH ECO MED HUM LI LifeScience.News Sanofi’s $15 Billion Patent Cliff: A 2026 Strategic Roadmap Analyzing the Dupixent monopoly, the €2.24B Tolebrutinib setback, and the high-stakes race for Amlitelimab.
AL Alexis Hinkle Kymera Therapeutics Взлетает После Расширения Sanofi Исследований Лекарства от Кожных Заболеваний Ключевые моменты
SOC AI MED OL Olívia Lacenová Sanofi’s bold ambitions in AI:Pioneering collaboration with OpenAI and Formation BIO A few days ago, French pharmaceutical company Sanofi entered into a major partnership with OpenAI and Formation Bio to better advance its…
ART ECO GEN BIO CA CASHFLOW.RECIPES Novavax Soars On Sanofi Deal, But Q1 Earnings Disappoint The vaccine maker Novavax watched its stock spike on Friday after the company announced a major deal with the French pharma giant Sanofi…